Opinion in Belgium

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

UCB/Schwarz: a leading CNS proposition moves a step closer

The $5.5 billion takeover of Schwarz Pharma by Belgian rival UCB looks likely to go ahead, as preliminary figures show that UCB has received tenders in excess of 76% of the share capital of Schwarz Pharma. In addition to generating significant synergies, the deal is expected to create a leading neurology-focused pharmaceuticals group.

Published By Datamonitor
12 Dec 2006
CommentWire
CommentWire

Solvay, Wyeth and Lundbeck: high expectations for schizophrenia drug

Results of safety and efficacy studies presented by Solvay, Lundbeck and Wyeth demonstrate that bifeprunox improved stability in schizophrenia patients versus placebo. The favorable weight and metabolic profile of bifeprunox is likely to boost patient compliance and will be a key differentiating factor for this drug when it enters the market.

Published By Datamonitor
07 Dec 2006
CommentWire
CommentWire

Belpex: one small leap for European wholesale market development

Europe's largest power exporter, France, has agreed to wholesale power market coupling with its lowland neighbors, Belgium and the Netherlands. Multinational day-ahead trading is scheduled to commence at Belpex later in November. While this represents a forward step towards a single European energy market, it alone will not redress underlying market inefficiencies.

Published By Datamonitor
09 Nov 2006
ResearchWire
ResearchWire

Belgo-Dutch wealth management: onshore liquid assets set to grow

Published By Datamonitor
28 Sep 2006
CommentWire
CommentWire

UCB: continuing the European Mid-Pharma consolidation craze

Having enjoyed past success from acquisitions, Belgian-based UCB is now looking to Schwarz Pharma, with its impressive late-stage pipeline, to boost its growth potential. This merger agreement is the latest in a recent 'acquisition frenzy', and highlights the current trend towards consolidation in the European pharmaceutical sector.

Published By Datamonitor
26 Sep 2006
CommentWire
CommentWire

Ahold/Delhaize: a merger of convenience

Dutch retailer Ahold and smaller rival Delhaize are in talks, with a merger between the two seen by many as the most plausible outcome. Ahold's and Delhaize's business operations may well be split along geographical lines, with Ahold running a future European division while Delhaize could affect the turnaround of Ahold's underperforming US arm.

Published By Datamonitor
21 Sep 2006
CommentWire
CommentWire

ImmunoMedics/UCB: looking to lupus

ImmunoMedics' shares have risen by around 14% after the company announced a profitable licensing deal with UCB for epratuzumab, a B-cell targeted therapy with promise in autoimmune disorders, specifically lupus. The deal should also prove a good move for UCB, which is gaining the rights to a promising drug candidate with blockbuster potential.

Published By Datamonitor
11 May 2006
CommentWire
CommentWire

Lukoil: brand new to western forecourts

Lukoil is keen to continue its charge across the European forecourt retailing sector as displayed by its interest in the soon-to-be-auctioned portfolio of ChevronTexaco forecourt retailing sites in the Benelux countries. With upstream infrastructure already in place, the capture of such a valuable retail network will ensure Lukoil achieves its goal of establishing its brand as a major player.

Published By Datamonitor
11 May 2006
CommentWire
CommentWire

New Look: furthering its French foray

New Look chief executive Phil Wrigley says there will now be a second phase of trials of New Look stores outside the UK. New Look already operates the 228-strong Mim chain in France, and the retailer is examining how the two chains could work alongside each other. This cautious expansion plan should generate further growth prospects in the future.

Published By Datamonitor
18 Apr 2006
Expert View
Expert View

Ofgem hints at intervention over price spikes but affirmative action still needed

After a long period of inaction by Ofgem over the issue of wholesale price spikes, recent signals have emerged pointing to a possible new, and more vociferous, desire by the regulator to address the issue. However it remains to be seen if this rhetoric will translate into Ofgem finally taking the required assertive course of action.

Published By Datamonitor
13 Feb 2006

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.